Mark J. Alles
Chief Commercial Officer, CELGENE CORP /DE/.
Companies
- Syros Pharmaceuticals, Inc.Board member Dec 20, 2019 to Sep 19, 20231
- BioMarin PharmaceuticalBoard member Jan 5, 2022 to May 24, 20232
- Turning Point Therapeutics, Inc.Board member May 26, 2021 to Aug 17, 20223
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
BioMarin Pharmaceutical BMRN15,095 shares4$826.5K at $54.75May 23, 2023- Syros Pharmaceuticals, Inc.3,666 shares5Sep 16, 2023
- Turning Point Therapeutics, Inc.0 shares6Aug 17, 2022
As of each latest filing. The line shows shares held over time.
Recent filings
- Sep 16, 2023Exercised options 2,666 shares of Syros Pharmaceuticals, Inc.5
- May 23, 2023Granted 4,190 shares of BioMarin Pharmaceutical4
- Oct 31, 2022Bought 3,625 shares at $86.75 of BioMarin Pharmaceutical7
- Aug 17, 2022Returned to company 2,000 shares at $76.00 of Turning Point Therapeutics, Inc.6
- May 24, 2022Granted 4,980 shares of BioMarin Pharmaceutical8
- Jan 3, 2022Granted 2,300 shares of BioMarin Pharmaceutical9
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7SEC EDGARForm 4 filed Nov 2, 2022
- 8SEC EDGARForm 4 filed May 26, 2022
- 9SEC EDGARForm 4 filed Jan 5, 2022